Valuation: Sanofi

Market Cap 91.8B 105B 85.37B 78.34B 147B 10,065B 149B 1,014B 396B 4,948B 392B 384B 17,109B P/E 2026 *
11.5x
P/E 2027 * 10.6x
Enterprise Value 101B 115B 94.32B 86.55B 163B 11,121B 165B 1,120B 438B 5,467B 434B 424B 18,904B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 1.94x
Free-Float
89%
Yield 2026 *
5.57%
Yield 2027 * 5.9%
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer 51 11/09/2023
Director TitleAgeSince
Director/Board Member 60 30/04/2019
Director/Board Member 57 28/04/2020
Director/Board Member 64 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 104B
+0.79%+1.72%+48.91%+161.12% 1,057B
+1.20%+3.70%+54.75%+53.38% 624B
+0.53%+1.60%+35.49%+80.58% 454B
+1.60%+6.25%+33.95%+29.84% 341B
-0.60%+1.52%+35.68%+39.76% 297B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 215B
+1.15%+2.78%+22.02%+59.92% 201B
-0.69%-3.28%+14.73%+67.23% 162B
Average +0.41%+0.77%+25.93%+51.96% 401.55B
Weighted average by Cap. +0.65%+1.57%+35.73%+77.70%

Financials

2026 *2027 *
Net sales 46.94B 53.45B 43.66B 40.06B 75.27B 5,147B 76.43B 518B 203B 2,531B 201B 196B 8,749B 50.04B 56.97B 46.53B 42.7B 80.23B 5,486B 81.47B 553B 216B 2,697B 214B 209B 9,326B
Net income 8.33B 9.49B 7.75B 7.11B 13.36B 913B 13.56B 92B 35.94B 449B 35.61B 34.84B 1,553B 9.22B 10.5B 8.58B 7.87B 14.79B 1,011B 15.02B 102B 39.8B 497B 39.43B 38.58B 1,719B
Net Debt 9.63B 10.97B 8.96B 8.22B 15.44B 1,056B 15.68B 106B 41.55B 519B 41.17B 40.28B 1,795B 5.52B 6.28B 5.13B 4.71B 8.85B 605B 8.99B 60.95B 23.81B 298B 23.59B 23.08B 1,029B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
76.36EUR
Average target price
95.60EUR
Spread / Average Target
+25.20%

Quarterly revenue - Rate of surprise